Morgan Stanley trimmed its stake in Sientra Inc (NASDAQ:SIEN) by 1.4% during the second quarter, HoldingsChannel reports. The institutional investor owned 141,723 shares of the medical instruments supplier’s stock after selling 1,960 shares during the period. Morgan Stanley’s holdings in Sientra were worth $873,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Wells Fargo & Company MN grew its position in shares of Sientra by 127.1% in the 2nd quarter. Wells Fargo & Company MN now owns 52,594 shares of the medical instruments supplier’s stock valued at $324,000 after buying an additional 29,430 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Sientra during the 2nd quarter worth $652,000. AWM Investment Company Inc. purchased a new position in Sientra during the 2nd quarter worth $2,156,000. Private Advisor Group LLC purchased a new position in Sientra during the 2nd quarter worth $62,000. Finally, Schroder Investment Management Group purchased a new position in Sientra during the 2nd quarter worth $7,700,000. 89.27% of the stock is currently owned by hedge funds and other institutional investors.
Several brokerages have issued reports on SIEN. ValuEngine raised shares of Sientra from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd. BidaskClub raised shares of Sientra from a “sell” rating to a “hold” rating in a research report on Thursday, October 10th. Stephens set a $16.00 price objective on shares of Sientra and gave the stock a “buy” rating in a research report on Friday, August 9th. Craig Hallum lowered their price objective on shares of Sientra from $20.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, July 25th. Finally, Zacks Investment Research raised shares of Sientra from a “sell” rating to a “hold” rating in a research report on Tuesday. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $15.75.
Sientra (NASDAQ:SIEN) last issued its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported ($0.45) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.49) by $0.04. Sientra had a negative net margin of 151.96% and a negative return on equity of 123.80%. The company had revenue of $22.41 million for the quarter, compared to the consensus estimate of $20.05 million. During the same period last year, the firm posted ($0.72) EPS. Sientra’s revenue for the quarter was up 32.8% on a year-over-year basis. As a group, equities analysts expect that Sientra Inc will post -2.42 earnings per share for the current year.
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Featured Article: Trading Strategy Methods and Types
Want to see what other hedge funds are holding SIEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sientra Inc (NASDAQ:SIEN).
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.